Skip 
Navigation Link

1215 South Walnut Ave.
Demopolis, AL 36732 map map 

Access to Care: 334.289.2410

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Opioid Rxs Decreasing, But Not for All DoctorsAfter Chinese Infant Gene-Editing Scandal, U.S. Health Officials Join Call for a BanAre 'Inactive' Ingredients in Your Drugs Really So Harmless?Need to Be Vaccinated? Try Your Local PharmacyBystanders Key to Cutting Cardiac Arrest DeathsMany Black Americans Live in Trauma Care 'Deserts'FDA Issues Asbestos Warning About Some Claire's Cosmetic ProductsFDA to Crack Down on Retailers That Keep Selling Tobacco to KidsBlood Donation by Teen Girls May Raise Anemia RiskNurses' Long Hours, Moonlighting Could Pose Patient Safety RiskBerkeley's Efforts Suggest Soda Taxes Do Cut Soda SalesOpioid Overdose Deaths Quadruple, Centered in 8 StatesPayments for Research Can Lead to Lies: StudyFDA Aims to Strengthen Sunscreen RulesAre Primary Care Doctors Prepared to Discuss Cancer Treatment?FDA Fell Short in Preventing Fentanyl Abuse Crisis, Report ClaimsPrimary Care Doctors Help Boost Life Spans, But More Are NeededMore Car Crashes Tied to Drivers High on OpioidsPoor Whites Bear the Brunt of U.S. Opioid Crisis, Studies FindFDA to Tighten Oversight of SupplementsAs U.S. Measles Outbreaks Spread, Why Does 'Anti-Vax' Movement Persist?Even Brief EMS Delay Can Cost Lives After Car CrashHealth Tip: Know Your Family's Medical HistoryPatients With Primary Care Docs May Get Better Health CareBlood Donors Needed as Cold Weather Freezes U.S. SupplyAHA: Medical Experts 'Sound the Alarm' on Medical MisinformationWhite House Plan to Disclose Drug Prices May Not Drive Down Costs: StudyCan Artificial Intelligence Read X-Rays?Virtual Doctor Visits Get High Marks in New SurveyBig Pharma's Marketing to Docs Helped Trigger Opioid Crisis: StudyDisrupted Sleep Plagues Hospital Patients, But New Program Might HelpOpioid Prescriptions Almost Twice as Likely for Rural vs. Urban AmericansClimate Change Already Hurting Human Health, Review ShowsCalling All Blood Donors …Even Older Drugs Are Getting Steep Price Hikes, Study FindsAs Medical Marketing Soars, Is Regulation Needed?Radiation Doses From CT Scans Vary WidelyU.S. Leads Health Care Spending Among Richer Nations, But Gets LessIs Your State a Hotspot for Obesity-Linked Cancers?Health Tip: Choose the Right DoctorFDA Warns Companies on Dangerous, Unapproved Stem Cell TreatmentsMore U.S. Kids Dying From Guns, Car AccidentsRoad Rules on Smartphone Use Are Saving Bikers' Lives, TooAHA: Should Pacemakers, Defibrillators Be Recycled -- and Reused in Others?California Farm Tied to E. coli Outbreak Expands Recall Beyond Romaine LettuceHealth Tip: Use Medical Devices SafelyCalifornia Farm Implicated in Outbreak of E. coli Tied to Romaine LettuceFentanyl Now the No. 1 Opioid OD KillerHospitalizations Rising Among the HomelessElectronic Health Records Bogging Docs Down
Questions and AnswersVideosLinksBook Reviews
Related Topics

Health Insurance
Healthcare

White House Plan to Disclose Drug Prices May Not Drive Down Costs: Study

HealthDay News
by -- Robert Preidt
Updated: Jan 25th 2019

new article illustration

FRIDAY, Jan. 25, 2019 (HealthDay News) -- By itself, a Trump administration plan to make drug companies disclose the cost of their medicines in TV ads is unlikely to help tame drug prices, a new study shows.

Researchers did find that revealing the cost of expensive drugs in ads would significantly lower patient demand for those drugs, but that impact largely vanished when the ads included a modifier, such as an explanation that the drug would be low-cost or free with insurance coverage or other discounts.

"Will price disclosure work at all? The answer is yes: price disclosure works, absent anything else," said study co-author Bill Tayler, a professor of accounting at Brigham Young University in Salt Lake City.

"But in a world where pharmaceutical companies behave logically, they will surely use a modifier of sorts that would unwind the entire benefit of this legislation," Tayler added in a university news release.

The study included 580 participants who were told to imagine they had recently been diagnosed with type 2 diabetes and were then shown one of five ads for a fictional diabetes prescription drug.

One version of the ad did not disclose the drug's price, while the other four mentioned either a low ($50 a month) or a high ($15,500 a month) price. Two ads were modified to say that eligible patients may be able to get the drug for free because of insurance coverage or coupon availability.

Participants who saw the ad with the high-price and no modifier were much less likely to say they'd ask their doctor about the drug, ask their insurance provider about the drug, research the drug online, or take the drug.

But those who saw the ads with high prices and modifying language were still interested in the drug, the findings showed.

According to study co-author Ge Bai, an associate professor of accounting at Johns Hopkins University, "Price disclosure in drug ads works only under the 'tell the price, only the price, nothing but the price' scenario."

The proposal to include prices in drug ads is opposed by the pharmaceutical industry.

Tayler concluded that "the suggested policy is unlikely to do harm, but it is also unlikely to help much to control pharmaceutical prices. This is not the most effective route and it could be very costly in terms of the lawsuits that are going to result. Why fight the legal battle if it's not going to work?"

The study was published Jan. 22 in JAMA Internal Medicine.

More information

The American Hospital Association has more on rising drug prices.